Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

42.77 +2.58 (+6.41%)
Delayed Quote Updated: 1:58 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets 
From FN Media
Via GlobeNewswire
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. 
From FN Media
Via GlobeNewswire
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
From Equity Insider
Via GlobeNewswire
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
From The DJS Law Group
Via Business Wire
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi &amp; Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Soon: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NOVO URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Contact Levi &amp; Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO
From DJS Law Group
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.